A phase IIA study of tisotumab vedotin (Humax - TF-ADC) in patients with relapsed, recurrent and/or metastatic cervical cancer

Vergote, I; Concin, N; Dean, E; Lassen, U; De Bono, JS; Drew, Y; Machiels, JP; Nielsen, D; Arkenau, T; Forster, M; Jones, R; Slomovitz, B; Spicer, J; Johnson, M; Cornez, N; GENNIGENS, Christine; Fulton, B; Basse, L; Lisby, S; Coleman, R; Hong, DS

Paper published in a journal (Scientific congresses and symposiums)

Vergote, I; Concin, N; Dean, E et al.

2017 • In Annals of Oncology, 28 (suppl 5), p. 331

Peer Reviewed verified by ORBi

Permalink
https://hdl.handle.net/2268/220956

Files (2)Send to Details Statistics Bibliography Similar publications

Files

Full Text

A phase IIA study of Tisotumab Vedotin ... abstract CG.ppt.pdf

Publisher postprint (94.46 kB)

Request a copy

Annexes

A phase IIA study of Tisotumab Vedotin ... CG.ppt.pdf

Publisher postprint (641.48 kB)

Request a copy

All documents in ORBi are protected by a user license.

Send to

RIS BibTex APA Chicago Permalink X Linkedin

Details

Keywords :

oncology; metastatic cervical cancer

Disciplines :

Oncology

Author, co-author :

Vergote, I

Concin, N

Dean, E

Lassen, U

De Bono, JS

Drew, Y

Machiels, JP

Nielsen, D

Arkenau, T

Forster, M

More authors (11 more)

Language :

English

Title :

A phase IIA study of tisotumab vedotin (Humax - TF-ADC) in patients with relapsed, recurrent and/or metastatic cervical cancer

Publication date :

2017

Event name :

ESMO Congress

Event place :

Madrid, Spain

Event date :

08 - 12 September 2017

Audience :

International

Journal title :

Annals of Oncology

ISSN :

0923-7534

eISSN :

1569-8041

Publisher :

Oxford University Press, London, United Kingdom

Volume :

Issue :

suppl 5

Pages :

331

Peer reviewed :

Peer Reviewed verified by ORBi

Available on ORBi :

since 02 March 2018

Statistics

Number of views

126 (3 by ULiège)

Number of downloads

0 (0 by ULiège)

More statistics